Biophytis (EPA:ALBPS) | WebDisclosure

Basculer en Français

9807	Companies
196724	Keywords
127731	Articles
104589	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 07/15/2025 at 07:00, 6 months 21 days ago

Biophytis Partners in AI with Lynx Analytics to Accelerate Drug Discovery for Sarcopenia
Biophytis partners with Lynx Analytics to accelerate drug discovery for sarcopenia through AI collaboration. The partnership aims to develop small molecule drugs for muscle preservation and regeneration

Biophytis Drug Discovery AI Sarcopenia Lynx Analytics
REGULATED PRESS RELEASE

published on 07/15/2025 at 07:00, 6 months 21 days ago

Biophytis s’associe à Lynx Analytics dans le domaine de l’IA pour accélérer la découverte de médicaments contre la sarcopénie
Biophytis s'associe à Lynx Analytics pour accélérer la découverte de médicaments contre la sarcopénie. Partenariat stratégique alliant IA et sciences de la vie

Biophytis Intelligence Artificielle Sarcopénie Découverte De Médicaments Lynx Analytics
PRESS RELEASE

published on 07/15/2025 at 06:59, 6 months 21 days ago

Biophytis s’associe à Lynx Analytics dans le domaine de l’IA pour accélérer la découverte de médicaments contre la sarcopénie
Biophytis annonce un partenariat avec Lynx Analytics pour accélérer la découverte de médicaments contre la sarcopénie en utilisant l'IA. Objectif : identifier des molécules pour traiter la perte musculaire chez les personnes âgées

Biophytis IA Médicaments Sarcopénie Lynx Analytics
BRIEF

published on 07/11/2025 at 08:19, 6 months 25 days ago

Biophytis : Résultats 2024 et Perspectives 2025

Résultats Financiers Biophytis Partenariats Sarcopénie Obésité
BRIEF

published on 07/11/2025 at 08:19, 6 months 25 days ago

Biophytis Reports 2024 Financial Results and Strategy for 2025

Drug Discovery Partnerships Biophytis Financials 2025 Strategic Plans Phase 2 And Phase 3 Trials
PRESS RELEASE

published on 07/11/2025 at 08:16, 6 months 25 days ago

Biophytis dévoile ses résultats 2024 et ses perspectives pour 2025
Biophytis dévoile ses résultats 2024 et ses perspectives pour 2025 avec le lancement d'études de phase 2 dans l'obésité et de phase 3 dans la sarcopénie, renforcement de partenariats et de la plateforme de découverte de médicaments

Biophytis Partenariats Résultats 2024 Études Cliniques Perspectives 2025
REGULATED PRESS RELEASE

published on 07/11/2025 at 08:14, 6 months 25 days ago

Biophytis dévoile ses résultats 2024 et ses perspectives pour 2025
Biophytis révèle ses résultats 2024 et perspectives 2025 avec lancement d'études cliniques et renforcement de sa plateforme technologique de découverte de médicaments. Communiqué de presse publié par Biophytis SA

Biophytis Résultats 2024 Études Cliniques Découverte De Médicaments Perspectives 2025
REGULATED PRESS RELEASE

published on 07/11/2025 at 08:14, 6 months 25 days ago

Biophytis Reports 2024 Financial Results and 2025 Outlook
Biophytis announces 2024 financial results, 2025 outlook. Initiates Phase 2 study in obesity, Phase 3 study in sarcopenia. Strengthens drug discovery platform. Resumes trading on Euronext Growth Paris

Financial Results Biophytis Drug Discovery Phase 3 Phase 2
BRIEF

published on 07/08/2025 at 07:05, 6 months 28 days ago

Biophytis Highlights Longevity Innovation at ARC 2025

Innovation Biophytis Longevity Sarcopenia ARC 2025
BRIEF

published on 07/08/2025 at 07:05, 6 months 28 days ago

Biophytis présente à la Conférence mondiale sur le vieillissement et le rajeunissement 2025

Innovation Biophytis Longévité Sarcopénie ARC 2025

Accesswire

Published on 02/05/2026 at 09:05, 2 hours 24 minutes ago

BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery
Published on 02/05/2026 at 01:35, 9 hours 54 minutes ago

Dr. Ruben Shiffman Files Early Warning Report in Respect of Greenland Resources
Published on 02/05/2026 at 00:00, 11 hours 29 minutes ago

Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus
Published on 02/04/2026 at 22:25, 13 hours 4 minutes ago

55 North Mining Announces Flow-Through Financing
Published on 02/04/2026 at 18:00, 17 hours 29 minutes ago

Lithium South AGSM Update

View all ACCESSWIRE

EQS Group

Published on 02/05/2026 at 11:16, 13 minutes ago

FUCHS strengthens its presence in Türkiye with the complete takeover of the joint venture OPET FUCHS
Published on 02/05/2026 at 11:00, 29 minutes ago

CHANGES TO THE BOARD OF DIRECTORS
Published on 02/05/2026 at 10:48, 40 minutes ago

EQS-Adhoc: Evonik Industries AG: Executive Board adjusts dividend policy
Published on 02/05/2026 at 10:05, 1 hour 23 minutes ago

VT Markets Powers Reliable Gold Trading Amid Extreme Market Volatility
Published on 02/05/2026 at 10:05, 1 hour 23 minutes ago

Signing of strategic technology supply and offtake agreement with Carester, US$20 million equity investment from the Industrial Development Corporation, and commencement of DFS for the Zandkopsdrift magnet rare earths and battery grade manganese

Les Echos

Published on 02/04/2026 at 18:04, 17 hours 25 minutes ago

Capital et droits de vote au 31 janvier 2026
Published on 02/04/2026 at 18:04, 17 hours 25 minutes ago

Total number of voting rights and shares making up the share capital at January 31, 2026
Published on 02/04/2026 at 17:45, 17 hours 44 minutes ago

Information concerning the total number of voting rights and shares 2026 01 31
Published on 02/04/2026 at 17:45, 17 hours 44 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 02/04/2026 at 17:45, 17 hours 44 minutes ago

Janvier 2026

View all LES ECHOS COMFI WIRE